Comprehensive Therapy

, Volume 32, Issue 3, pp 182–188

Use of antiplatelet drugs in secondary prevention in patients with atherothrombotic disease

Original Article

Abstract

Unless there are contraindications to the use of aspirin, aspirin should be used to treat patients with acute myocardial infarction (MI) and continued indefinitely to decrease vascular death, nonfatal MI, and nonfatal stroke. Chlopidogrel added to aspirin is beneficial in the treatment of patients with acute ST-elevation MI. Patients with unstable angina pectoris or non-ST-elevation MI should be treated with aspirin plus clopindogrel for at least 9 mo to decease vascular death, nonfatal MI, and nonfatal stroke. Patients with prior MI should be treated indefinitely with aspirin and with clopidogrel if aspirin is contraindicated. Patients with ischemic stroke should be treated with either aspirin or clopidogrel indefinitely. Clopidogrel is significantly more effective than aspirin in reducing vascular death, nonfatal MI, and nonfatal stroke in patients with peripheral arterial disease

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a longterm health care facility. J Gerontol Med Sci 2002:57A:M45-M46.Google Scholar
  2. 2.
    Arow WS, Ahn C. Prevaluence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women≥62 years of age. Am J Cardiol 1994; 74:64–65.CrossRefGoogle Scholar
  3. 3.
    Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practices. J Am Geriatr Soc 1999;47:1255–1256.PubMedGoogle Scholar
  4. 4.
    Aronow WS. What is the appropriate treatment of hypertension in elders? J Gerontol: Med Sci 2002;57A:M483-M486.Google Scholar
  5. 5.
    Aronow WS. Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular evants? J Gerontol: Med Sci 2005:60A:M591-M592.Google Scholar
  6. 6.
    Roth GJ, Majderus PW. The mechanism of the effect of aspirin on human platelets: I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624–632.PubMedCrossRefGoogle Scholar
  7. 7.
    Mills DC, Puri R, Hu CJ, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992:12:430–436.PubMedGoogle Scholar
  8. 8.
    Hardisty RM, Powling MJ, Nokes TJ. The action of ticlopidine on human platelets. Studies on aggregation. secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost 1990:64:145–150.Google Scholar
  9. 9.
    Best LC, McGuire MG, Jones PB, et al. Mode of action of dipyridamole on human platelets. Thromb Res 1979;16:367–379.PubMedCrossRefGoogle Scholar
  10. 10.
    Lefkovits J, Polw EF, Topol EJ. Platelet glycoprotein IIb/IIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553–1559.PubMedCrossRefGoogle Scholar
  11. 11.
    Bhatt DL, Topo EJ. Current role of platelet glycoprotein Iib/IIa inhibitors in acute coronary syndromes. JAMA 2000;284:1549–1558.PubMedCrossRefGoogle Scholar
  12. 12.
    Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein Iib/IIIa antagonists. A meta-analysis of phase III multicenter randomized trials. Circulation 2001;103:201–206.PubMedGoogle Scholar
  13. 13.
    Antithrombotic Trialists Collaboration. Collaborative meta-analyis of randomised trials of antiplatelet therapy for prevention of death, myiocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71–86.CrossRefGoogle Scholar
  14. 14.
    Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarcition: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infraction). Circulation 1999;100:1016–1030.PubMedGoogle Scholar
  15. 15.
    Krumholz HM, Radford MJ, Ellerbeck FM, et al. Aspirin in the treatment of acute myocardial infarction, in elederly Medicare benetificiaries. Patterns of use and outcomes. Circulation 1995;92:2481–2847.Google Scholar
  16. 16.
    COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607–1621.CrossRefGoogle Scholar
  17. 17.
    Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179–1189.PubMedCrossRefGoogle Scholar
  18. 18.
    Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics The PCI-CLARIATY study. JAMA 2005;294:1224–1232.PubMedCrossRefGoogle Scholar
  19. 19.
    The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.CrossRefGoogle Scholar
  20. 20.
    Peters RJG, Mehta SR, Fox KAA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes. Observations from the Clopidogrtel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108:1682–1687.PubMedCrossRefGoogle Scholar
  21. 21.
    Budaj A, Yusuf S, Mehta SR, et al. Enefit of clopidogrel in patients with acute coronary syndromes, without ST-segment elevation in various risk groups. Circulation 2002;106:1622–1626.PubMedCrossRefGoogle Scholar
  22. 22.
    Mehta SR, Yusuf S, Peters RJG, et al. Effects of pertreatment with clopidogrel and aspirin followed by long-term therapy in ptients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–533.PubMedCrossRefGoogle Scholar
  23. 23.
    Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. UAMA 2002;2411:2411–2420.Google Scholar
  24. 24.
    Gamble SM, Saulle LN, Aronow WS, et al. Incidence of in-hospital mortality or nonfatal myocardial infarction or nonfatal stroke in 216 dabetics and 552 nondiabetics undergoing percutaneous coronary intervention with stenting. Am. J Therap, in press.Google Scholar
  25. 25.
    Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2002;40:1366–1374.PubMedCrossRefGoogle Scholar
  26. 26.
    Krumholz HM, Radford MJ, Ellerbeck EJ, et al. Aspirin for secondary prevention after acute mycocardial infarction in the elderly: prescribed use and outcome. Ann Intern Med 1996;124:292–298.PubMedGoogle Scholar
  27. 27.
    Aronow WS, Ahn C. Reduction of coronary events with aspiria in older patients with prior myocardial infarction treated with and without staitins. Heaet Disease 2002;4:159–161.CrossRefGoogle Scholar
  28. 28.
    CAPRIE Steering Committee. A randomised, blinded, trial of clopi dogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–1339.CrossRefGoogle Scholar
  29. 29.
    Cannon CP, on behalf of the CAPRIE Investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 2002;90:760–762.PubMedCrossRefGoogle Scholar
  30. 30.
    Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001:103:363–368.PubMedGoogle Scholar
  31. 31.
    Ghosh S, Ziesmer V, Aronow WS. Undeutilization of aspirin, beta blockers, angiodensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilzation of calcium channel blockers in older persons with coronary artery disease in an academic nursing home. J Geronto: Med Sci 2002;57A:M398-M400.Google Scholar
  32. 32.
    Sanal S, Aronow WS. Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensinconverting enzyme inhibitors. lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital dischrage in patients with coronary areaty disease. J Gerontol: Med Sci 2003;58A:M1046-M1048.Google Scholar
  33. 33.
    Nayak D, Aroow WS. Effect of ongoing educational program on the use of antiplatelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, and lipid-loweing drugs in patients with coronary aretery disease seen in an academic cardilogy clinic. Cardiol Rev 2005;13:95–97.PubMedCrossRefGoogle Scholar
  34. 34.
    Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk parients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1990;321:501–507.CrossRefGoogle Scholar
  35. 35.
    Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2 Dipyridamole and acetylasalicylic cid in the secondary prevention of stroke. J Neurol Sci 1996;143:1–13.PubMedCrossRefGoogle Scholar
  36. 36.
    The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665–1673.CrossRefGoogle Scholar
  37. 37.
    Diener HC, Bogousslasky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo,-controlled trial. Lancet 2004;364:331–337.PubMedCrossRefGoogle Scholar
  38. 38.
    Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305–1316.PubMedCrossRefGoogle Scholar
  39. 39.
    Roles P, Mikhailidis DP, Stansby G. Systematic review of antiplalet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease Br J Surg 2001;88:787–800.CrossRefGoogle Scholar
  40. 40.
    Hess H, Mietaschke A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. Lancet 1985;1:415–419.PubMedCrossRefGoogle Scholar
  41. 41.
    Giansante C, Calabrese S, Fisicaro M, et al. Treatment of intermittent claudication with antiplatelet agents. J Int Med Res 1990; 18:400–407.PubMedGoogle Scholar
  42. 42.
    Goldhaber SZ, Manson JE, Stampfer MJ, et al. Low-dose aspicin and subsequent periphereral arterial surgery in the Physician Health Study. Lancet 1992;340:143–145.PubMedCrossRefGoogle Scholar
  43. 43.
    Ranke C, Hecker H, Creutzig A, Alexander K. Dose-dependent effect of aspirin on carotid atheroscleosis. Circulation 1993;87:1873–1879.PubMedGoogle Scholar
  44. 44.
    Jackson MR, Clagett GP. Antithrombotic therapy in peripheral artenal occlusive disase. Chest 2001;119:283S-299S.PubMedCrossRefGoogle Scholar
  45. 45.
    Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608–1621.PubMedCrossRefGoogle Scholar
  46. 46.
    Sukhija R, Yalamanchili K, Aronow WS, et al. Clinical characteristics, risk factors, and medical treatment of 561 patients with peripheral arterial disease followed in an academic vascular surgery clinic. Cardiol Rev 2005;13:107–109.Google Scholar
  47. 47.
    Ness J, Aronow WS, Newkirk E, McDanel D Prevalence of symptomatc peripheral arterial disease, modifiable risk factors, and appropriate use of drugs in the treatment of older persons seen in a general medicine clinic. J Gerontol: Med Sci 2005; 60A:M255-M257.Google Scholar
  48. 48.
    Homes ER Jr. Amplatelet therapy after percutaneous coronary intervention. Cerebrovasc Dis 2006;21(Suppl 1):25–34.CrossRefGoogle Scholar
  49. 49.
    Stone GW, Aronow HD. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Mayo Clin Proc 2006;81:641–652.PubMedCrossRefGoogle Scholar

Copyright information

© ASCMS 2006

Authors and Affiliations

  1. 1.Division of of Geriatrics, Department of MedicineWestchester Medical Center/ New York Medical CollegeVahafla
  2. 2.Division of Pulmonary/Critical Care Medicine, Department of MedicineWestchester Medical Center/ New York Medical CollegeVahafla
  3. 3.Cardiology DivisionNew York Medical CollegValhalla

Personalised recommendations